Has Sandeep Mukherjee, MD received payments from drug or device companies?

Yes. Drug and device makers reported $145,167 in general payments to Sandeep Mukherjee, MD across 150 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sandeep Mukherjee, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sandeep Mukherjee, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sandeep Mukherjee, MD

Gastroenterology · Omaha, NENPI 1760432066

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $131,401 of the $145,167 with a category attached, or 90.5%. 14 manufacturers reported payments, led by Gilead at 52.6% of the total. 2025 is the largest year on record at $53,752, 3.5 times the $15,315 reported in 2019. Among gastroenterology clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$145,167in general payments, 2019–2025

Across 150 payments — averaging $967.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Gilead$76K
Ipsen Biopharmaceuticals, Inc$40K
Intercept Pharmaceuticals, Inc.$15K
Madrigal Pharmaceuticals$13K
Boston Scientific$725
Illumina, Inc.$190
plus $313 from 8 others

$304,038in research payments, 2019–2025

Across 92 payments — averaging $3304.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Intercept Pharmaceuticals, Inc.$269K
Intercept Pharma Europe Ltd.$20K
AbbVie$16K

What the payments were for

Consulting fees$1,2401%
Speaking & faculty fees$131,40191%
Travel & lodging$9,1076%
Food & beverage$3,4012%
Other$170%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Gilead	78	$76,397
Ipsen Biopharmaceuticals, Inc	17	$39,697
Intercept Pharmaceuticals, Inc.	11	$15,031
Madrigal Pharmaceuticals	20	$12,814
Boston Scientific	5	$725
Illumina, Inc.	1	$190
AbbVie	7	$123
Johnson & Johnson	5	$69
Sanofi	1	$28
Abbott	1	$28
Viiv Healthcare Company	1	$18
Lilly USA, LLC	1	$17
Welch Allyn	1	$17
Bristol Myers Squibb	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Epclusa$48,587
IQIRVO$34,406
Livdelzi$21,704
OCALIVA$14,880
REZDIFFRA$12,350
GENERAL POLYPECTOMY$668
Oncology Testing$190

How this compares

$145,167 in reported general payments places this provider in the 95th percentile of 89 gastroenterology providers in Nebraska.

See all gastroenterology providers in Nebraska →

Medicare billing

Part B allowed, 2024

$57,439

Medicare patients

330

Services billed

464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl	179	$2,717
ClenpiqSod Picosulf/Mag Ox/Citric Ac	11	$1,907
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl	61	$878
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates	14	$824
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg	13	$249
Omeprazole	20	$189
Pantoprazole Sodium	11	$81
Carvedilol	11	$64

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Omaha

Benjamin HallOmaha$154K
Rowen ZettermanOmaha$119K
Derrick EicheleOmaha$54K
Joshua EvansOmaha$34K
Michael SchaferOmaha$30K
Peter MannonOmaha$30K
Helen Fasanya-UptagraftOmaha$26K
Rajani RangrayOmaha$15K
Grant HutchinsOmaha$15K
Trevor PearsonOmaha$13K

See the full list for Nebraska →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →